In Pfizer, J&J’s Innovation Centers, Incubators Lie Paths To Indian Innovation

Pfizer India Has Two Start-ups Close To Commercialization

Executives from J&J, Pfizer and Johns Hopkins share ideas on driving Indian biopharma innovation via innovation centers and incubators set up in association with academic institutions. On the other side of the table, Indian academia highlights the need for industry participation in skill building and the perils of ‘targeted thinking’

Statue of a man in thought
Industry And Academia Shared Ideas On Paths To Indian Innovation • Source: Alamy

Multinational companies are no stranger to collaboration with academia and while tie-ups like GlaxoSmithKline plc-Harvard University, AstraZeneca PLC-Columbia University and Pfizer Inc.-University of California have been successful, the most obvious example during recent times has been Astra Zeneca’s tie-up with the University of Oxford for a COVID-19 vaccine.

At the recent Global Innovation Summit – 2021, executives from Johnson & Johnson, Pfizer and Johns Hopkins University drew on their experiences to share partnership-fostering ideas that ranged from proactively tapping

More from R&D

More from Scrip

Finance Watch: Deerfield Closes $600m-Plus VC Fund; Gates Speeds Up Health Investments

 
• By 

Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pharma Left Hanging After US/UK Trade Pact

 
• By 

An ‘historic economic prosperity deal’ does not include the sector.